Serum levels of soluble CD8 are increased in patients with B chronic lymphocytic leukemia

Semenzato, Gianpietro; Siviero, Fosca; Vinante, Fabrizio; Zambello, Renato; Trentin, Livio; Agostini, Carlo; Adami, Fausto; Vincenzi, C.; Zanotti, Roberta; Zuppini, B.; Chilosi, Marco; Pizzolo, Giovanni

doi:10.1016/0277-5379(89)90300-3

Cited by 15 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14,15,39 In keeping with this, the highest levels were detected in the patients with most advanced disease, especially in UPN 474 who had signs of progressive disease at SCT. After transplant, the levels fell in all patients and showed a definite relationship to the response of the disease, except in UPN 474 who, at 200 days post-SCT, had peak values which were probably due to an exacerbation of chronic GVHD.…”

Section: Discussionmentioning

confidence: 49%

Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease

et al. 2000

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 49%

Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease

et al. 2000

View full text Add to dashboard Cite

“…However, although various arguments (cleavage of membrane IL-2Ra by MMP-9 [39] (Fig. 3), increased concentrations of serum sIL-2Ra or intratumoral CD25 and MMP-9 in the same group of cancer patients [14][15][16][17][18][19]46] and also in asthmatic patients [47] the overlapping role of the two parameters as prognostic factors in cancer patients [20,21,26,27]) has suggested a possible link between expression of MMP-9 and release of sIL-2Ra into serum, we did not find any relationships between these two factors.…”

Section: Discussionmentioning

confidence: 99%

“…Significantly elevated serum levels of sIL-2Ra and MMP-9 have been found in patients with renal cell carcinoma, B chronic lymphocytic leukaemia and non-small cell lung carcinoma compared to healthy controls [14][15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships

Agueznay

Badoual

Hans

et al. 2007

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryIn a series of 84 head and neck patients, a statistically significant correlation was observed between high serum soluble interleukin (IL)-2 receptor alpha (sIL-2Ra) (P = 0·034) and metalloproteinase-9 (MMP-9) concentrations (P = 0·036) at diagnosis and a shorter survival of these patients. As MMP-9 has been shown to mediate cleavage of IL-2Ra (CD25) by preactivated T cells, we looked for a relationship between MMP-9 expression and soluble IL-2Ra serum concentrations in these cancer patients. We did not find any correlation between intratumoral expression of MMP-9 or serum MMP-9 concentrations and serum sIL-2Ra levels. These results led us to reassess the role of MMP-9 in the release of sIL-2Ra. Treatment of Kit225 leukaemic cells with recombinant MMP-9 slightly decreased membrane CD25 expression and was associated with an increased concentration of sIL-2Ra in the supernatants. However, using a selective inhibitor of MMP-9 we did not succeed in specifically inhibiting the release of sIL-2Ra by the Kit225 cell line or by phytohaemagglutinin (PHA)-activated peripheral blood mononuclear cells. In addition, in a preclinical mouse model, basal serum sIL-2Ra concentrations and sIL-2Ra production by activated cells were not altered in MMP-9-deficient mice compared to wild-type mice. Interestingly, a broad spectrum metalloproteinase inhibitor inhibited the release of sIL-2Ra by PHAactivated peripheral blood mononuclear cells, suggesting that in contrast with current views concerning the major role of MMP-9 in the cleavage of membrane IL-2Ra, other proteases are involved in the shedding of sIL-2Ra. MMP-9 and sIL-2Ra appear therefore as independent prognostic markers in head and neck cancers.

show abstract

“…In fact, abnormally high blood levels of sIL-2R have been detected in several clinical states characterized by suppression of cellular immunity, including AIDS and metastatic solid tumours (Kloster et al, 1987;Rovelli et al, 1988). Moreover, recent clinical studies have also pointed out that elevated sIL-2R levels play a negative prognostic role in various malignancies, such as metastatic solid tumours, hairy cell leukaemia, chronic leukaemia, acute lymphoblastic leukaemia and lymphomas Semenzato et al, 1987;Pui et al, 1988aPui et al, , 1989Rovelli et al, 1988;Steis et al, 1988;Chilosi et al, 1989;Motoi et al, 1989;Gause et al, 1992a;Enblad et al, 1995).…”

mentioning

confidence: 99%

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications

Viviani

Camerini²,

Bonfante³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

The aim of this study was to assess the prognostic role of soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease (HD) both in the achievement of complete remission (CR) and in predicting disease relapse. Between August 1988 and June 1993 sIL-2R serum levels were measured in 174 untreated patients; in 137 of them evaluation was repeated at the end of treatment and in 132 also during the follow-up. Baseline sIL-2R levels (mean+/-standard error) were significantly higher in patients than in 65 healthy control subjects (1842+/-129 U ml(-1) vs 420+/-10 U ml(-10, P< 0.0001). At the end of treatment 135 out of 137 evaluated patients achieved complete response (CR) and their mean sIL-2R serum levels were significantly lower than those at diagnosis (635+/-19 U ml(-1) vs 1795+/-122 U ml(-1), P=0.0001). After a median follow-up of 5 years, sIL-2R remained low in 114 patients in continuous CR, while they increased in 9 out of 12 patients (75%) who relapsed. However, a temporary increase was also observed in six patients (5%) still in CR. Treatment outcome in terms of freedom from progression was linearly related to sIL-2R levels. Our study confirms that patients with untreated HD have increased baseline levels of sIL-2R compared with healthy subjects and that their pretreatment values may be an indication of disease outcome similar to other conventional prognostic factors, such as number of involved sites, presence of B symptoms and extranodal extent.

show abstract

Serum levels of soluble CD8 are increased in patients with B chronic lymphocytic leukemia

Cited by 15 publications

References 16 publications

Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease

Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease

Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications

Contact Info

Product

Resources

About